Cargando…

Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma

BACKGROUND: The efficacy of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is primarily ascribed as a source of neutralizing anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. However, the composition of other immune components in CCP and their potential rol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonny, Tania S, Patel, Eshan U, Zhu, Xianming, Bloch, Evan M, Grabowski, M Kate, Abraham, Alison G, Littlefield, Kirsten, Shrestha, Ruchee, Benner, Sarah E, Laeyendecker, Oliver, Shoham, Shmuel, Sullivan, David, Quinn, Thomas C, Casadevall, Arturo, Pekosz, Andrew, Redd, Andrew D, Tobian, Aaron A R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717355/ https://www.ncbi.nlm.nih.gov/pubmed/33553467 http://dx.doi.org/10.1093/ofid/ofaa574

Ejemplares similares

SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors
por: Benner, Sarah E, et al.
Publicado: (2020)

Absence of pathogenic viruses in COVID‐19 convalescent plasma
por: Kandathil, Abraham J., et al.
Publicado: (2022)

Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population
por: Klein, Sabra, et al.
Publicado: (2020)

CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the entire SARS-CoV-2 proteome and show kinetics of early differentiation
por: Kared, Hassen, et al.
Publicado: (2020)

Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
por: Natarajan, Harini, et al.
Publicado: (2021)

SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma therapy
por: Natarajan, Harini, et al.
Publicado: (2020)

Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers
por: Heaney, Christopher D., et al.
Publicado: (2021)

Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers
por: Heaney, Christopher D., et al.
Publicado: (2021)

Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality
por: Morgenlander, William, et al.
Publicado: (2020)

Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals
por: Saraf, Sharada, et al.
Publicado: (2022)

Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals
por: Saraf, Sharada, et al.
Publicado: (2022)

Antibody Attributes that Predict the Neutralization and Effector Function of Polyclonal Responses to SARS-CoV-2
por: Natarajan, Harini, et al.
Publicado: (2021)

Antibody attributes that predict the neutralization and effector function of polyclonal responses to SARS-CoV-2
por: Natarajan, Harini, et al.
Publicado: (2022)

Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers
por: Patel, Eshan U., et al.
Publicado: (2020)

Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers
por: Patel, Eshan U., et al.
Publicado: (2021)

CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants
por: Redd, Andrew D, et al.
Publicado: (2021)

A Hemagglutination-Based Semiquantitative Test for Point-of-Care Determination of SARS-CoV-2 Antibody Levels
por: Kruse, Robert L., et al.
Publicado: (2021)

Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals
por: Redd, Andrew D, et al.
Publicado: (2021)

CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants
por: Redd, Andrew D, et al.
Publicado: (2021)

Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8(+) T-Cell Epitopes Identified in COVID-19 Convalescent Individuals
por: Redd, Andrew D., et al.
Publicado: (2022)

LB-18. Broad and Prevalent SARS-CoV-2 CD8+ T Cell Response in Recovered COVID-19 Individuals Demonstrates Kinetics of Early Differentiation
por: Kared, Hassen, et al.
Publicado: (2020)

Comparing the Epidemiology and Health Burden of Lyme Disease and Babesiosis Hospitalizations in the United States
por: Bloch, Evan M, et al.
Publicado: (2022)

Prescription Antibiotic Use Among the US population 1999–2018: National Health and Nutrition Examination Surveys
por: Petersen, Molly R, et al.
Publicado: (2021)

Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial
por: Baksh, Sheriza N, et al.
Publicado: (2023)

The Assessment of Convalescent Plasma Efficacy against COVID-19
por: Casadevall, Arturo, et al.
Publicado: (2020)

Prevalence, Magnitude, and Genotype Distribution of Urinary Cytomegalovirus (CMV) Shedding Among CMV-Seropositive Children and Adolescents in the United States
por: White, Jodie L, et al.
Publicado: (2019)

The Potential Role of Passive Antibody-Based Therapies as Treatments for Monkeypox
por: Bloch, Evan M., et al.
Publicado: (2022)

Spike-protein proteolytic antibodies in COVID-19 convalescent plasma contribute to SARS-CoV-2 neutralization
por: McConnell, Scott A., et al.
Publicado: (2023)

Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children
por: Gordon, Oren, et al.
Publicado: (2022)

Demographic and clinical correlates of acute and convalescent SARS-CoV-2 infection among patients of a U.S. emergency department
por: Laeyendecker, Oliver, et al.
Publicado: (2021)

High Proportion of Indeterminate QuantiFERON-TB Gold In-Tube Results in an Inpatient Population Is Related to Host Factors and Preanalytical Steps
por: Fabre, Valeria, et al.
Publicado: (2014)

High Viral Specific Antibody Convalescent Plasma Effectively Neutralizes SARS-CoV-2 Variants of Concern
por: Li, Maggie, et al.
Publicado: (2022)

Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
por: Bloch, Evan M, et al.
Publicado: (2023)

Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
por: Li, Maggie, et al.
Publicado: (2022)

A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients With Coronavirus 2019
por: Maor, Yasmin, et al.
Publicado: (2023)

Convalescent plasma in outpatients with COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Public Knowledge and Attitudes Toward Clinical Trials in the COVID-19 Era
por: Patel, Eshan U., et al.
Publicado: (2022)

Age Patterns of HSV-2 Incidence and Prevalence in Two Ugandan Communities: A Catalytic Incidence Model Applied to Population-Based Seroprevalence Data
por: Whittles, Lilith K, et al.
Publicado: (2023)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Use of convalescent plasma in the treatment of COVID-19
por: Joyner, Michael J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7hcob4ks9t5qogdkvcelc6i39o